Landiolol free base | CAS#133242-30-5 | beta-blocker

MedKoo Cat#: 598283 | Name: Landiolol free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Landiolol, also known as LDLL600 and ONO 1101, is an ultra-short-acting β1-blocker. Landiolol is a highly selective beta-1-adrenoreceptor antagonist (the selectivity for beta-1-receptor blockade is 255 times higher than for beta-2-receptor blockade) that inhibits the positive chronotropic effects of the catecholamines adrenaline and noradrenaline on the heart, where beta-1-receptors are predominantly located.

Chemical Structure

Landiolol free base

CAS#133242-30-5 (free base)

Theoretical Analysis

MedKoo Cat#: 598283

Name: Landiolol free base

CAS#: 133242-30-5 (free base)

Chemical Formula: C25H39N3O8

Exact Mass: 509.2737

Molecular Weight: 509.60

Elemental Analysis: C, 58.92; H, 7.71; N, 8.25; O, 25.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

133242-30-5 (free base) 144481-98-1 (HCl)

Synonym

Landiolol; LDLL600; LDLL 600; LDLL-600; ONO1101; ONO-1101; ONO 1101;

IUPAC/Chemical Name

(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-((S)-2-hydroxy-3-((2-(morpholine-4-carboxamido)ethyl)amino)propoxy)phenyl)propanoate

InChi Key

WMDSZGFJQKSLLH-AIBWNMTMSA-N

InChi Code

InChI=1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22?/m0/s1

SMILES Code

O=C(OCC1OC(C)(C)OC1)CCC2=CC=C(OC[C@@H](O)CNCCNC(N3CCOCC3)=O)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 509.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015 Aug 4;4(3):251-7. doi: 10.5492/wjccm.v4.i3.251. eCollection 2015 Aug 4. PubMed PMID: 26261777; PubMed Central PMCID: PMC4524822. 2: Xiao J, He P, Zou Q, Zhao Y, Xue Z, Deng X, Li S, Guo Q, Tao G, Yang T, Lang Z, He J, Wang X. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Anesth. 2015 Mar;27(2):120-8. doi: 10.1016/j.jclinane.2014.07.003. Epub 2014 Nov 28. PubMed PMID: 25434501. 3: Kunisawa T, Yamagishi A, Suno M, Nakade S, Higashi R, Kurosawa A, Sugawara A, Matsubara K, Iwasaki H. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients. J Anesth. 2015 Apr;29(2):198-205. doi: 10.1007/s00540-014-1908-5. Epub 2014 Sep 4. PubMed PMID: 25186494. 4: Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. Adv Ther. 2014 Apr;31(4):426-39. doi: 10.1007/s12325-014-0111-2. Epub 2014 Mar 19. Erratum in: Adv Ther. 2014 May;31(5):577-8. PubMed PMID: 24643403; PubMed Central PMCID: PMC4003342. 5: Ishigaki D, Arimoto T, Iwayama T, Hashimoto N, Kutsuzawa D, Kumagai Y, Nishiyama S, Takahashi H, Shishido T, Miyamoto T, Watanabe T, Kubota I. Prevention of immediate recurrence of atrial fibrillation with low-dose landiolol after radiofrequency catheter ablation. J Arrhythm. 2015 Oct;31(5):279-85. doi: 10.1016/j.joa.2015.02.003. Epub 2015 Apr 4. PubMed PMID: 26550083; PubMed Central PMCID: PMC4600890. 6: Mori K, Yamada K, Fukuda T, Mitsui T, Kitamura T, Yamaguchi D, Ando J, Wada I, Nomura S, Shimizu N, Seto Y. Landiolol hydrochloride for early postoperative tachycardia after transthoracic esophagectomy. Surg Today. 2014 May;44(5):848-54. doi: 10.1007/s00595-013-0615-4. Epub 2013 May 15. PubMed PMID: 23674201. 7: Li L, Ai Q, Lin L, Ge P, Yang C, Zhang L. Efficacy and safety of landiolol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015 Jul 15;8(7):10265-73. eCollection 2015. Review. PubMed PMID: 26379818; PubMed Central PMCID: PMC4565201. 8: Wang M, Zhang Q, Hua W, Zhou W, Huang M, Wang H. Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects. Drug Res (Stuttg). 2014 Mar;64(3):141-5. doi: 10.1055/s-0033-1354368. Epub 2013 Sep 3. PubMed PMID: 24002929. 9: Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. Adv Ther. 2014 Apr;31(4):440-50. doi: 10.1007/s12325-014-0116-x. Epub 2014 Apr 23. PubMed PMID: 24756366; PubMed Central PMCID: PMC4003343. 10: Sezai A, Osaka S, Yaoita H, Ishii Y, Arimoto M, Hata H, Shiono M. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventricular Dysfunction (PLATON) trial. J Thorac Cardiovasc Surg. 2015 Oct;150(4):957-64. doi: 10.1016/j.jtcvs.2015.07.003. Epub 2015 Jul 10. PubMed PMID: 26254752. 11: Kunisawa T, Yamagishi A, Suno M, Nakade S, Honda N, Kurosawa A, Sugawara A, Tasaki Y, Iwasaki H. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in patients with peripheral arterial disease. Ther Clin Risk Manag. 2015 Jan 17;11:107-14. doi: 10.2147/TCRM.S74867. eCollection 2015. PubMed PMID: 25653534; PubMed Central PMCID: PMC4303402. 12: Niwa Y, Koike M, Iwata N, Kobayashi D, Tanaka C, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy. Hepatogastroenterology. 2014 Sep;61(134):1546-51. PubMed PMID: 25436340. 13: Hirano M, Yamashina A, Hara K, Ikari Y, Jinzaki M, Iino M, Yamaguchi T, Tanimoto M, Kuribayashi S; Landiolol Hydrochloride Study Group. A randomized, double-blind, placebo-controlled, phase III study of the short-acting β1-adrenergic receptor blocker landiolol hydrochloride for coronary computed tomography angiography in Japanese patients with suspected ischemic cardiac disease. Clin Drug Investig. 2014 Jan;34(1):53-62. doi: 10.1007/s40261-013-0149-y. PubMed PMID: 24174275; PubMed Central PMCID: PMC3889825. 14: Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013 Jun;73(9):959-77. doi: 10.1007/s40265-013-0077-4. Review. Erratum in: Drugs. 2013 Jul;73(11):1255. PubMed PMID: 23760735. 15: Nakamura Y, Yamaji K, Saho T, Matsuzaki Z, Yuda I, Soga Y, Shirai S, Ando K, Nobuyoshi M. A comparison of bolus injection of landiolol versus oral administration of propranolol before cardiac computed tomography. Springerplus. 2014 Feb 17;3:93. doi: 10.1186/2193-1801-3-93. eCollection 2014. PubMed PMID: 24634807; PubMed Central PMCID: PMC3951651. 16: Aoyama H, Otsuka Y, Aoyama Y. Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection. Gen Thorac Cardiovasc Surg. 2016 Dec;64(12):735-741. Epub 2016 Aug 23. PubMed PMID: 27553581. 17: Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci. 2016 Sep 20;92:64-73. doi: 10.1016/j.ejps.2016.06.022. Epub 2016 Jun 29. PubMed PMID: 27373605. 18: Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908-16. Epub 2013 Mar 15. PubMed PMID: 23502991. 19: Yamashita T, Saitoh T, Matsushita M. Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. J Cardiol. 2015 Jul;66(1):69-72. doi: 10.1016/j.jjcc.2014.09.008. Epub 2014 Nov 6. PubMed PMID: 25454208. 20: Miyake K, Fujita Y, Yoshizawa S, Tomita M, Miyazu M, Sento Y, Yoshimura S, Sobue K. Effects of landiolol on refractory tachyarrhythmia after total cavopulmonary connection: a retrospective, observational, cohort study. J Anesth. 2016 Apr;30(2):331-6. doi: 10.1007/s00540-015-2119-4. Epub 2015 Dec 23. PubMed PMID: 26699148.